Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilherme Fleury Perini

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control SubjectsPriscilla Brito da Silva, Guilherme Fleury Perini, Luciana de Andrade Pereira, et al.
Transplantation and Cellular Therapy|October 14, 2025
Peripheral Blood or Bone Marrow Grafts for Mismatched Unrelated Donors with Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisLeonardo Javier Arcuri, Victor Hugo Glasser Natal, Mariana Nassif Kerbauy, et al.
Einstein (Sao Paulo, Brazil)|January 14, 2016
Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemiaGuilherme Fleury Perini, Fabio Pires de Souza Santos, Iracema Esteves, et al.
Medicine|March 30, 2017
A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin AmericaFabio Freire José, Lucila Nassif Kerbauy, Guilherme Fleury Perini, et al.
Blood|May 2, 2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, et al.
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
Blood Advances|October 13, 2021
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphomaPier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, et al.
Revista Brasileira De Hematologia E Hemoterapia|August 24, 2017
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program ExperienceTalita Máira Bueno da Silveira da Rocha, Sergio Costa Fortier, Thais Rodrigues da Cunha Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
International Journal of Cancer|October 13, 2017
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma RegistryIrene Biasoli, Nelson Castro, Marcia Delamain, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control SubjectsPriscilla Brito da Silva, Guilherme Fleury Perini, Luciana de Andrade Pereira, et al.
Transplantation and Cellular Therapy|October 14, 2025
Peripheral Blood or Bone Marrow Grafts for Mismatched Unrelated Donors with Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisLeonardo Javier Arcuri, Victor Hugo Glasser Natal, Mariana Nassif Kerbauy, et al.
Einstein (Sao Paulo, Brazil)|January 14, 2016
Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemiaGuilherme Fleury Perini, Fabio Pires de Souza Santos, Iracema Esteves, et al.
Medicine|March 30, 2017
A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin AmericaFabio Freire José, Lucila Nassif Kerbauy, Guilherme Fleury Perini, et al.
Blood|May 2, 2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, et al.
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
Blood Advances|October 13, 2021
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphomaPier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, et al.
Revista Brasileira De Hematologia E Hemoterapia|August 24, 2017
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program ExperienceTalita Máira Bueno da Silveira da Rocha, Sergio Costa Fortier, Thais Rodrigues da Cunha Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
International Journal of Cancer|October 13, 2017
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma RegistryIrene Biasoli, Nelson Castro, Marcia Delamain, et al.
Pageof 3